FAQ

APC 8015

Known as: APC-8015, APC8015, APC8015 Vaccine 
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2015
024620002015

Related topics

Related topics

3 relations
Dendritic Cells

Narrower (1)

Provenge

Broader (1)

sipuleucel-T

Related mentions per year

Related mentions per year

1949-2018
19401960198020002020
APC 8015
Dendritic Cells
sipuleucel-T
Provenge

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015
  • Robert Bok
  • Therapeutics and clinical risk management
  • 2008
The body's immune system has some capacity to recognize and attack cancerous growths, including prostate cancer. However, various… (More)
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2006
2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local…
BACKGROUND APC8015 (sipuleucel-T) is a cellular prostate cancer vaccine containing autologous antigen-presenting cells (APC… (More)
Is this relevant?
Review
2006
Review
2006
Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
  • Drugs in R&D
  • 2006
Sipuleucel-T [APC 8015, Provenge] is an autologous, dendritic cell-based vaccine under development with Dendreon Corporation for… (More)
Is this relevant?
2005
2005
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
BACKGROUND Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen… (More)
Is this relevant?
2004
2004
Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express… (More)
Is this relevant?
2003
2003
Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for patients with hormone-refractory prostate cancer with a Gleason score <or= 7.
 
Is this relevant?
Review
2002
Review
2002
Technology evaluation: APC-8015, Dendreon.
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?